AGTR2 and leukemia: The recipient mice transplanted with Agtr2-KD AML cells show faster leukemia development and shorter survival in both MA9 (median survival of days, control 33.5 vs Agtr2-KD 31.5; 92.9% (BM), 72.6% (liver; LV), 84.4% (peripheral blood; PB), and 59.6% (spleen, SP) increase in ratios of leukemia cells in Agtr2-KD vs control) and AE9 AML (median survival of days, control 87.5 vs Agtr2-KD 66.5; 88.2% (BM), 321.1% (LV), 133.2% (PB), and 250.5% (SP) increase in ratios of leukemia cells in Agtr2-KD vs control) models.